

David B. Bennett, Ph.D.

David has more than 17 years experience in the pharmaceutical industry directing CMC activities from discovery to commercial launch. Most recently he built and led the R&D Analytical organization at Nektar Therapeutics, and led the joint Pfizer-Nektar Formulation & Analytical Working Group for Exubera, the first inhalable insulin. Prior to Nektar, David held positions of increasing responsibility for analytical and novel delivery systems development at Roche Bioscience, Syntex, and SmithKline Beecham. David holds degrees in Chemistry and Pharmaceutics from the University of Utah and is currently providing consulting in aerosol product CMC.